Cost-Effectiveness Evaluation of a Remote Monitoring Programme Including Lifestyle Education Software in Type 2 Diabetes: Results of the Educ@dom Study.
Cost-effectiveness
EDUC@DOM
Economic assessment
Lifestyle management
Tele-education
Telemonitoring
Type 2 diabetes
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
03
12
2021
accepted:
18
01
2022
pubmed:
9
2
2022
medline:
9
2
2022
entrez:
8
2
2022
Statut:
ppublish
Résumé
Telemedicine programs using health technological innovation to remotely monitor the lifestyles of patients with type 2 diabetes (T2D) can improve glycaemic control and thus reduce the incidence of complications as well as management costs. In this context, an assessment was made of the 1-year and 2-year cost-effectiveness of the EDUC@DOM telemonitoring and tele-education program. The EDUC@DOM study was a multicentre randomized controlled trial conducted between 2013 and 2017 that compared a telemonitoring group (TMG) to a control group (CG) merged with health insurance databases to extract economic data on resource consumption. Economic analysis was performed from the payer perspective, and direct costs and indirect costs were considered. The clinical outcome used was the intergroup change in glycated haemoglobin (HbA1c) levels from baseline. Missing economic data were imputed using multiple imputation, and fitted values from a generalized linear mixed model were used to calculate the incremental cost-effectiveness ratio (ICER). Bootstrapped 95% confidence ellipses were drawn in the cost-effectiveness plan. The main analysis included data from 256 patients: 126 in the TMG and 130 in the CG. Incremental costs over 1 and 2 years were equal to €2129 and €5101, respectively, in favour of the TMG. Once imputed and adjusted for confounding factors, the TMG trends to a 21% cost decrease over 1 and 2 years of follow-up (0.79 [0.58; 1.08], p = 0.1452 and 0.79 [0.61; 1.03], p = 0.0879, respectively). The EDUC@DOM program led to a €1334 cost saving and a 0.17 decrease in HbA1c over 1 year and a €3144 cost saving and a 0.14 decrease in HbA1c over 2 years. According to the confidence ellipse, EDUC@DOM was a cost-effective strategy. This study provides additional economic information on telemonitoring and tele-education programs to enhance their acceptance and promote their use. In the light of this work, the EDUC@DOM program is a cost-saving strategy in T2D management. This trial was registered in the Clinical Trials Database on 27 September 2013 under no. NCT01955031 and bears ID-RCB no. 2013-A00391-44.
Identifiants
pubmed: 35133640
doi: 10.1007/s13300-022-01207-1
pii: 10.1007/s13300-022-01207-1
pmc: PMC8991290
doi:
Banques de données
ClinicalTrials.gov
['NCT01955031']
Types de publication
Journal Article
Langues
eng
Pagination
693-708Subventions
Organisme : French Ministry of Health
ID : 12-018-0078
Organisme : Conseil Régional Midi-Pyrénées
ID : 11052617
Organisme : Conseil Régional Midi-Pyrénées
ID : 13050630
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Artif Intell Med. 2008 Mar;42(3):213-27
pubmed: 18261889
Lancet. 1998 Sep 12;352(9131):837-53
pubmed: 9742976
Diabetes Care. 2009 Jul;32(7):1202-4
pubmed: 19366971
Pharmacoepidemiol Drug Saf. 2017 Aug;26(8):954-962
pubmed: 28544284
J Am Coll Cardiol. 2008 Dec 16;52(25):2119-26
pubmed: 19095128
Front Endocrinol (Lausanne). 2019 Sep 18;10:640
pubmed: 31620092
Diabetes Ther. 2021 Jul;12(7):2059-2075
pubmed: 34160791
Phys Ther. 2008 Nov;88(11):1254-64
pubmed: 18801858
Diabetologia. 2020 Dec;63(12):2582-2594
pubmed: 32968866
J Med Internet Res. 2020 Sep 17;22(9):e16053
pubmed: 32940613
BMC Health Serv Res. 2018 Jun 26;18(1):495
pubmed: 29940936
Diabetes Res Clin Pract. 2018 Oct;144:200-212
pubmed: 30205184
Eur J Health Econ. 2017 Apr;18(3):293-312
pubmed: 26975444
N Engl J Med. 1993 Sep 30;329(14):977-86
pubmed: 8366922
Rev Med Interne. 2015 Jun;36(6):411-7
pubmed: 25547954
Medicine (Baltimore). 2014 Dec;93(28):e312
pubmed: 25526482
Diabetes Care. 2010 Apr;33(4):745-7
pubmed: 20103547
Pharmacoeconomics. 2011 Mar;29(3):189-98
pubmed: 21309615
Med Decis Making. 1990 Jul-Sep;10(3):212-4
pubmed: 2115096
Diabetes Technol Ther. 2018 Jul;20(7):492-500
pubmed: 29812965
Diabetes Care. 2018 Dec;41(12):2669-2701
pubmed: 30291106
Diabetes Care. 1992 Feb;15(2):204-12
pubmed: 1547677
Stat Med. 2000 Dec 15;19(23):3219-36
pubmed: 11113956
Diabetol Metab Syndr. 2017 Jul 11;9:52
pubmed: 28702091
Diabetes Care. 2012 Nov;35(11):2156-60
pubmed: 22851599
Diabete Metab. 1995 Feb;21(1):26-33
pubmed: 7781839
BMC Med Res Methodol. 2014 Jun 05;14:75
pubmed: 24903709
Diabetes Metab. 2001 Apr;27(2 Pt 1):139-47
pubmed: 11353880
BMC Health Serv Res. 2020 Nov 16;20(1):1043
pubmed: 33198734